SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Belite Bio Reports Unaudited Third Quarter 2026 Financial Results and Provides a Corporate Update

SAN DIEGO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc NASDAQ:BLTE (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its financi…

BLTE

Related stories